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ABSTRACT
Introduction: The purpose of this study was to 
assess the efficacy of the insulin tolerance test 
(ITT) in predicting the effectiveness of insulin 
sensitizers in type 2 diabetic patients.  Methods: 
We retrospectively reviewed 360 consecutive 
patients with type 2 diabetes admitted to Osaka 
University Hospital, Japan. In 163 of these 
hospitalized patients, insulin resistance was 
evaluated by the ITT after their blood glucose 
level was ameliorated. We then analyzed the 
association between their clinical characteristics 
and their glycemic control 6 months after 
discharge. Results: The rate constant for plasma 
glucose disappearance, KITT, was negatively 
correlated with body mass index (BMI), waist 
circumference (WC), and visceral fat area (VFA). 
The median value of KITT was 1.56 (%/min). In 
the KITT >1.56 group (n=81), hemoglobin A1c
(HbA1c) significantly increased in both patients 
treated with insulin sensitizers (n=10) and 
patients not treated with insulin sensitizers 
(n=71). In the KITT ≤1.56 group (n=82), HbA1c 
significantly increased in patients not treated 
with insulin sensitizers (n=60); however, it was 
maintained well in the patients treated with 
insulin sensitizers (n=22). When the patients 
were divided and analyzed according to the 
median values of BMI, WC, or VFA, the glycemic 
control change was not different between the 
two groups with insulin sensitizers for each 
parameter. Conclusion: Insulin sensitizers were 
effective in type 2 diabetic patients with high 
insulin resistance estimated by the ITT. The ITT 
could be useful to predict the effectiveness of 
insulin sensitizers.
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INTRODUCTION 
Type 2 diabetes mellitus is characterized 
by decreased insulin secretion and insulin 
sensitivity in varying degrees.1-4 In Japanese 
diabetic patients, impaired insulin secretion 
is emphasized rather than insulin resistance,5122 Diabetes Ther (2010)  1(2):121-130.
but insulin resistance also plays an important 
role in the deterioration of glucose tolerance.6,7 
Recent studies have shown that the homeostasis 
model assessment of insulin resistance 
(HOMA-IR) in Japanese patients with type 2 
diabetes was significantly higher than that 
for subjects with normal glucose tolerance.7,8 
The prevalence of metabolic syndrome (MetS), 
which is characterized by insulin resistance9 
defined by the criteria proposed by a Japanese 
study group,10 has reached as much as 45.9% 
in male and 28.0% in female Japanese type 2 
diabetic patients.11 Therefore, it is important to 
consider insulin sensitizers in treating Japanese 
type 2 diabetics as well as insulin secretagogues. 
Insulin sensitizers, such as pioglitazone and 
metformin, are available, and are expected 
to improve glycemic control in patients with 
insulin resistance. However, it has not yet been 
fully clarified which characteristics in diabetic 
patients determine the efficiency of insulin 
sensitizers in each patient.
The euglycemic hyperinsulinemic clamp 
is regarded as the gold standard technique for 
measurement of in-vivo insulin action,12 but 
it requires sophisticated equipment, several 
hours of work, and considerable expense to 
use. By contrast, the insulin tolerance test 
(ITT) is simpler, easy to perform, and a more 
practical method than the clamp. The glucose 
disappearance rate calculated from the ITT 
(KITT) has a close correlation with glucose clamp 
studies.13-15 We hypothesized that we could 
predict the effectiveness of insulin sensitizers 
in patients using the results of the ITT. In this 
study, we retrospectively reviewed consecutive 
subjects with type 2 diabetes mellitus admitted 
to Osaka University Hospital, Japan, whose 
insulin resistance had been evaluated by the 
ITT. We analyzed the association between the 
effectiveness of insulin sensitizers and KITT in 
these patients.
MATERIALS AND METHODS 
Patients
We retrospectively reviewed 360 consecutive 
subjects with type 2 diabetes mellitus admitted 
to Osaka University Hospital from 2001 to 2008. 
Following admission, all of the patients were 
treated by diet alone or diet plus insulin for at 
least 2 weeks, until fasting plasma glucose (FPG) 
was below 7.0 mmol/L. After FPG reached the 
target level, insulin resistance was evaluated 
by the ITT, and 32 patients among them were 
treated with insulin sensitizers, according to the 
judgment of physicians. Then, we retrospectively 
analyzed the clinical characteristics and the 
glycemic control 6 months after discharge.  
Measurements
The ITT was performed after an overnight fast, 
as previously described.13 Blood samples were 
collected every 3 minutes for 15 minutes after 
intravenous regular insulin injection (0.1 U/kg). 
The plasma glucose half-time (t½) was calculated 
from the slope of the least square analysis of 
the plasma glucose concentrations from 3 to 
15 minutes after insulin injection. KITT was 
calculated with the formula 0.693/t½. 
A 75 g oral glucose tolerance test and a 
glucagon stimulation test were performed, 
as previously described.16 Plasma glucose 
concentrations were measured by the glucose 
oxidase method, and immunoreactive insulin 
and C-peptide levels were measured with enzyme 
immunoassay kits. For evaluation of glycemic 
control, the values of hemoglobin A1c (HbA1c) 
at the time of discharge (or within 1 month 
after discharge) and 6 months after discharge 
and the increments of HbA1c (∆HbA1c) between 
the two periods were used. The value for HbA1c
(%) is estimated as a National Glycohemoglobin Diabetes Ther (2010)  1(2):121-130. 123
Standardization Program (NGSP) equivalent 
value (%) calculated by the formula HbA1c
(%)=HbA1c (Japan Diabetes Society [JDS], %)+ 
0.4%, considering the relational expression of 
HbA1c (JDS, %) measured by the previous Japanese 
standard substance and measurement methods 
and HbA1c (NGSP).17 Plasma adiponectin levels 
were determined with an adiponectin enzyme-
linked immunosorbent assay (ELISA) kit (Otsuka 
Pharmaceutical Co. Ltd, Tokushima, Japan), as 
previously described.18 The visceral fat area (VFA) 
was estimated by computed tomography, or by 
abdominal bioelectrical impedance analysis, 
which was shown to correlate significantly with 
VFA determined by computed tomography.19
Statistical Analyses
Data are presented as the mean±standard 
deviation (SD). Comparison of variables 
between groups was done with the Mann-
Whitney nonparametric test, or an unpaired 
Student’s t test. Pearson’s correlation coefficient 
analysis was used to assess the cross-sectional 
relationships between KITT and other variables. 
Comparison of HbA1c at the time of discharge (or 
within 1 month after discharge) and 6 months 
after discharge in each group was done with a 
paired Student’s t test.  
RESULTS  
Insulin Tolerance Test
The ITT was performed in 163 out of 360 patients. 
The KITT of these patients ranged from 0.39%/
min to 8.9%/min, and the median value was 
1.56%/min. The body mass index (BMI), waist 
circumference (WC), and VFA were negatively 
correlated with KITT (r=–0.15, P=0.05; r=–0.25, 
P=0.003; and r=–0.23,  P=0.02, respectively) 
(Table 1).  
Patient Groups
The patients were divided into two groups 
according to the median value of KITT: KITT ≤1.56 
and KITT >1.56. Each of these two groups of patients 
were further divided into two subgroups according 
to treatment with or without insulin sensitizers at 
discharge. Insulin sensitizer treatment was with 
thiazolidinedione (pioglitazone) (TZD), biguanide 
(metformin or buformine) (BG), or both 
(TZD+BG). The KITT ≤1.56 group (n=82) included 
22 patients treated with insulin sensitizers (TZD, 
n=9; BG, n=10; TZD+BG, n=3). The KITT >1.56 
group (n=81) included 10 patients treated with 
insulin sensitizers (TZD, n=3; BG, n=7). Clinical 
data from these groups were investigated 
6 months after discharge (Figure 1).  
Clinical Characteristics of the Patients
The clinical characteristics of the patients of 
the KITT ≤1.56 group and the KITT >1.56 group 
Table 1. Correlation coefficients of relationships between 
KITT and various parameters in type 2 diabetic patients.
  r  P value
Age, years  –0.06  0.43
Body mass index, kg/m2  –0.15  0.05
Waist circumference, cm  –0.25  0.003
Visceral fat area, cm2  –0.23  0.02
HbA1c, (%)*  –0.05  0.53
Fasting plasma glucose, mmol/L†  –0.05  0.53
HbA1c, %†  –0.04  0.62
Urine C-peptide, nmol/day  0.09  0.26
Insulinogenic index, pmol/mmol  0.03  0.69
∆C-peptide, nmol/L  0.09  0.31
Adiponectin, μg/mL  0.05  0.61
*Value on admission.
†Value at the time of discharge or within 1 month after 
discharge. 
HbA1c=hemoglobin A1c; KITT=rate constant for plasma 
glucose disappearance calculated from the insulin tolerance 
test; r=Pearson’s correlation coefficient.124 Diabetes Ther (2010)  1(2):121-130.
are shown in Table 2. VFA was significantly 
greater in the KITT ≤1.56 group, compared with 
the KITT >1.56 group (P<0.05). Other parameters 
were not significantly different between the two 
groups. The number of patients using insulin at 
discharge was 45 in the KITT ≤1.56 group and 26 
in the KITT >1.56 group, and patients with insulin 
secretagogues numbered 38 and 40, respectively. 
The clinical characteristics of the groups with 
and without insulin sensitizers in the KITT ≤1.56 
group and the KITT >1.56 group are shown in 
Table 3. There was no significant difference 
in the characteristics, including markers of 
insulin secretion and resistance, between the 
KITT ≤1.56 group with insulin sensitizers, and the 
KITT ≤1.56 group without insulin sensitizers, as 
well as between the KITT >1.56 group with insulin 
sensitizers, and the KITT >1.56 group without 
insulin sensitizers. In the KITT ≤1.56 group, the 
number of patients using insulin at discharge 
was three (14%) in the group with insulin 
sensitizers, and 42 (70%) in the group without 
insulin sensitizers. In the KITT >1.56 group, the 
number of patients using insulin at discharge was 
two (20%) in the group with insulin sensitizers, 
and 24 (34%) in the group without insulin 
sensitizers. In two groups with insulin sensitizers, 
the number of patients using treatment other 
Type 2 diabetic patients (n=360)
Estimation of HbA1c 6 months later
Reduction of glucotoxicity (FPG <7.0 mmol/L)
Estimation of insulin resistance by ITT (n=163)
KITT ≤1.56 (%/min) (n=82)
TZD or BG (+) (n=22)
TZD
BG
TZD + BG
(n=9)
(n=10)
TZD
BG
(n=3)
(n=7)
(n=3)
TZD or BG (–) (n=60) TZD or BG (+) (n=10) TZD or BG (–) (n=71)
KITT >1.56 (%/min) (n=81)
Figure 1. Management protocol for type 2 diabetic patients. After hospitalization, patients were treated until fasting plasma 
glucose (FPG) was below 7.00 mmol/L. The insulin tolerance test (ITT) was performed in 163 of the patients to evaluate 
insulin resistance. According to the median value of the rate constant for plasma glucose disappearance calculated from 
the insulin tolerance test (KITT; 1.56%/min), the patients were divided into two groups: KITT ≤1.56 and KITT >1.56. These 
two groups were further divided into two subgroups: with or without insulin sensitizers at discharge. Insulin sensitizers 
were thiazolidinedione (pioglitazone) (TZD) and/or biguanide (metformin or buformine) (BG). Patient hemoglobin A1c 
(HbA1c) levels were evaluated at the time of discharge (or within 1 month after discharge) and 6 months later. Diabetes Ther (2010)  1(2):121-130. 125
than insulin sensitizers at discharge was 17 
(77.3%) for KITT  ≤1.56 and seven (70%) for 
KITT >1.56. In the KITT ≤1.56 group with insulin 
sensitizers, mean dosage of insulin sensitizers at 
the time of discharge was 23 (15-30) mg/day for 
pioglitazone, 750 (all 750) mg/day for metformin, 
and 112 (100-150) mg/day for buformine. In 
this group, mean dosage of insulin sensitizers 
6 months after discharge was 25 (15-30) mg/
day for pioglitazone, 718 (500-750) mg/day 
for metformin, and 110 (100-150) mg/day for 
buformine. In the KITT >1.56 group with insulin 
sensitizers, mean dosage of insulin sensitizers 
at the time of discharge was 20 (15-30) mg/
day for pioglitazone, 625 (500-750) mg/day 
for metformin, and 117 (100-150)  mg/day 
for buformine. In this group, mean dosage of 
insulin sensitizers 6 months after discharge 
was 20 (15-30) mg/day for pioglitazone, 583 
(500-750)  mg/day for metformin, and 125 
(100-150) mg/day for buformine.  
Glycemic Control After Discharge
Glycemic control around the time of discharge 
and 6 months after discharge are shown in 
Table  4. The levels of HbA1c significantly 
increased in the KITT ≤1.56 group without insulin 
sensitizers (7.3%±0.9% to 8.0%±1.7%, P=0.007), 
the KITT >1.56 group with insulin sensitizers 
Table 2. Clinical characteristics of the study subjects (total: KITT ≤1.56 and KITT >1.56). 
   Total  KITT ≤1.56  KITT >1.56
n (male/female)  163 (84/79)   82 (44/38)   81 (40/41)
Age, years  60.1±11.9  60.1±11.5  60.4±11.8
Body mass index, kg/m2  23.9±4.2  24.5±4.7  23.3±3.7
Waist circumference, cm  89.6±12.0 (n=141)  92.3±12.6* (n=72)  86.9±10.7 (n=69)
Visceral fat area, cm2  108.6±52.9 (n=106)  121.0±54.4* (n=52)  96.7±48.9 (n=54)
HbA1c, %†  9.67±1.86  9.82±1.66 (n=81)  9.63±1.77
Fasting plasma glucose, mmol/L‡  6.33±0.99  6.44±0.90  6.29±0.86 
HbA1c, %‡  7.13±0.90   7.22±0.87  7.04±0.92 
KITT, %/min  1.9±1.2  1.1±0.3**  2.7±1.3 
Urine C-peptide, nmol/day  21.5±14.6 (n=149)  20.3±14.5 (n=76)  22.8±14.7 (n=73)
∆C-peptide, nmol/L  0.72±0.41 (n=130)  0.68±0.42 (n=65)  0.75±0.39 (n=65)
Insulinogenic index, pmol/mmol  9.78±11.9 (n=141)  9.41±11.3 (n=69)   10.1±12.6 (n=72)
LDL-C, mmol/L  2.90±0.68 (n=162)  2.77±0.66*  3.04±0.68 (n=80)
HDL-C, mmol/L  1.26±0.36 (n=162)  1.22±0.34  1.30±0.38 (n=80)
TG, mmol/L  1.15±0.52 (n=162)  1.17±0.49  1.14±0.55 (n=80)
eGFR, mL/min/1.73 m2  87.7±25.7  89.5±28.6  85.8±22.3
Adiponectin, μg/mL  5.4±3.3 (n=121)  4.9±2.5 (n=57)  5.8±3.8 (n=64)
Data are mean±SD.
*P<0.05.
**P<0.0001; KITT≤1.56 versus KITT>1.56.
†Value on admission.
‡Value at the time of discharge or within 1 month after discharge. 
eGFR=estimated glomerular filtration rate; HbA1c=hemoglobin A1c; HDL-C=high-density lipoprotein cholesterol; 
KITT=rate constant for plasma glucose disappearance calculated from the insulin tolerance test; LDL-C=low-density 
lipoprotein cholesterol; TG=triglyceride.126 Diabetes Ther (2010)  1(2):121-130.
(6.6%±0.8% to 7.3%±1.1%, P=0.025), and the 
KITT >1.56 group without insulin sensitizers 
(7.1%±0.9% to 7.4%±1.5%, P=0.022). However, 
HbA1c did not increase in the KITT ≤1.56 
group with insulin sensitizers (7.1%±0.9% to 
7.0%±0.9%, P=not significant [NS]) (Table 4). In 
the KITT ≤1.56 group without insulin sensitizers, 
the ∆HbA1c (0.7%±1.6%) was higher than that 
in the KITT ≤1.56 group with insulin sensitizers 
(–0.1%±1.3%), but the difference was NS 
(P=0.087). Respective HbA1c changes in these 
subgroups are shown in Figure 2. 
When all of the patients were divided into 
two groups according to the median value of 
BMI (BMI ≥23.2, BMI <23.2), WC (WC ≥90.5, 
WC <90.5), or VFA (VFA ≥104.9, VFA <104.9), 
the levels of HbA1c did not change in both 
groups with insulin sensitizers (Table 4). When 
they were divided into two groups according to 
the values based on the obesity or abdominal 
obesity criteria of BMI (BMI ≥25, BMI <25), 
WC (WC ≥85 in men and WC ≥90 in women, 
WC <85 in men and WC <90 in women), or VFA 
(VFA ≥100, VFA <100) in Japan, the results were 
the same as above (data not shown). 
DISCUSSION
In this study, we have shown the possible 
usefulness of ITT for selecting patients for 
Table 3. Clinical characteristics of the study subjects with and without insulin sensitizers (KITT≤1.56 and KITT>1.56).
  KITT ≤1.56  KITT >1.56
   TZD or BG (+)   TZD or BG (–)   TZD or BG (+)   TZD or BG (–) 
n (male/female)  22 (12/10)  60 (32/28)  10 (8/2)  71 (32/39)
Age, years  59.9±11.9  60.2±11.4  62.7±14.3  60.1±11.5
Body mass index, kg/m2  24.4±2.7  24.5±5.2  24.2±2.1  23.2±5.8
Waist circumference, cm  91.7±9.3 (n=19)  92.5±13.7 (n=53)  91.5±7.8 (n=9)  86.2±11.0 (n=60)
Visceral fat area, cm2  118.7±43.5 (n=16)  122.1±59.2 (n=36)  115.2±52.1 (n=6)  94.4±48.6 (n=48)
HbA1c, %†  9.4±1.8 (n=21)  10.0±1.6  9.5±2.2  9.6±1.7
Fasting plasma glucose, mmol/L‡  6.43±0.91  6.35±1.17   6.26±0.82  6.29±0.87 
HbA1c, %‡  7.1±0.9  7.3±0.9   6.6±0.8  7.1±0.9 
KITT, %/min  1.2±0.3   1.1±0.3   2.2±0.8   2.8±1.3 
Urine C-peptide, nmol/day  20.2±14.8 (n=19)  20.3±14.6 (n=57)  24.9±12.8 (n=8)  22.6±15.0 (n=65)
∆C-peptide, nmol/L  0.82±0.41 (n=14)  0.65±0.42 (n=51)  0.87±0.56 (n=5)  0.74±0.38 (n=60)
Insulinogenic index, pmol/mmol  11.0±11.8 (n=19)   8.8±11.1 (n=50)  12.4±8.2 (n=8)   9.9±13.1 (n=64)
LDL-C, mmol/L  2.89±0.76  2.73±0.63  2.91±0.44  3.05±0.70 (n=70)
HDL-C, mmol/L  1.10±0.31*  1.26±0.34  1.26±0.33  1.31±0.39 (n=70)
TG, mmol/L  1.21±0.41  1.15±0.52  1.26±0.45  1.12±0.56 (n=70)
eGFR, ml/min/1.73m2  85.1±22.9  91.1±30.4  84.2±21.7  86.0±22.5
Adiponectin, μg/mL  4.8±2.2 (n=11)  4.9±2.6 (n=46)  5.6±2.1 (n=6)  5.8±4.0 (n=58)
Data are mean±SD.
*P<0.05, KITT ≤1.56, TZD or BG (+) versus KITT ≤1.56, TZD or BG (–).
†Value on admission.
‡Value at the time of discharge or within 1 month after discharge.
BG=biguanide (metformin or buformine); eGFR=estimated glomerular filtration rate; HbA1c=hemoglobin A1c; 
HDL-C=high-density lipoprotein cholesterol; KITT=rate constant for plasma glucose disappearance calculated from the insulin 
tolerance test; LDL-C=low-density lipoprotein cholesterol; TG=triglyceride; TZD=thiazolidinedione (pioglitazone).Diabetes Ther (2010)  1(2):121-130. 127
whom insulin sensitizers are effective for 
glycemic control. With insulin sensitizers, the 
glycemic control worsened in the group with 
a higher value of KITT, but was maintained well 
in the group with a lower value of KITT. There 
was also a tendency to keep good glycemic 
control after discharge with insulin sensitizers 
in the latter group, compared with in the 
former group. By contrast, the other parameters 
studied (BMI, WC, and VFA) were not useful 
for determining the effectiveness of insulin 
sensitizers. In previous reports, rosiglitazone, 
which is one of the TZDs, and metformin were 
effective for glycemic control of type 2 diabetic 
patients with and without obesity, defined 
by BMI.20,21 These results, in addition to ours, 
suggest that parameters other than KITT could 
not clearly discriminate the patients regarding 
the effectiveness of insulin sensitizers. It is 
speculated that KITT represents in-vivo insulin 
action in the whole body directly,13 while other 
parameters do not, though these parameters are 
regarded as the factors associated with insulin 
resistance. In our study, BMI, WC, and VFA had 
low correlation coefficients with KITT. In other 
previous reports, BMI and waist-to-hip ratio were 
not related to insulin resistance estimated by 
KITT.22 These results suggest that BMI, WC, and 
VFA may cause or reflect some partial aspects of 
insulin resistance.
Table 4. Glycemic control after discharge in all of the patients.
    At discharge*   After discharge† (%)  ∆HbA1c (%)  P value (%)
KITT ≤1.56, %/min  TZD or BG (+) (n=22)  7.1±0.9  7.0±0.9  –0.1±1.3  NS
  TZD or BG (–) (n=60)  7.3±0.9  8.0±1.7  0.7±1.6  0.0007
KITT >1.56, %/min  TZD or BG (+) (n=10)  6.6±0.8  7.3±1.1  0.7±0.9  0.025
  TZD or BG (–) (n=71)  7.1±0.9  7.4±1.5  0.3±1.2  0.022
BMI ≥23.2, kg/m2  TZD or BG (+) (n=18)  6.9±1.0  7.0±1.1  0.1±1.5  NS
  TZD or BG (–) (n=64)  7.3±0.9  7.9±1.9  0.6±1.8  0.014
BMI <23.2, kg/m2  TZD or BG (+) (n=14)  7.0±0.8  7.3±0.8  0.3±0.9  NS
  TZD or BG (–) (n=67)  7.1±0.8  7.5±1.4  0.5±1.0  0.0001
WC ≥90.5, cm  TZD or BG (+) (n=16)  6.8±1.0  6.9±1.1  0.1±1.5  NS
  TZD or BG (–) (n=55)  7.3±1.0  8.0±2.0  0.6±1.8  0.013
WC <90.5, cm  TZD or BG (+) (n=12)  7.0±0.8  7.4±0.7  0.3±0.9  NS
  TZD or BG (–) (n=58)  7.0±0.9  7.4±1.2  0.4±0.9  0.001
VFA ≥104.9, cm2  TZD or BG (+) (n=13)  7.1±1.0  7.2±1.0  0.1±1.7  NS
  TZD or BG (–) (n=40)  7.4±0.9  8.1±2.0  0.6±1.8  0.032
VFA <104.9, cm2  TZD or BG (+) (n=9)  6.9±1.0  7.0±0.9  0.1±1.1  NS
  TZD or BG (–) (n=44)  7.0±0.9  7.4±1.3  0.4±1.0  0.027
Data are mean±SD.
*At the time of discharge or within 1 month after discharge.
†At 6 months after discharge; ∆HbA1c was calculated from HbA1c 6 months after discharge minus that at the time of 
discharge or within 1 month after discharge.
BG=biguanide (metformin or buformine); BMI=body mass index; HbA1c=hemoglobin A1c; KITT=rate constant for 
plasma glucose disappearance calculated from the insulin tolerance test; NS=not significant; TZD=thiazolidinedione 
(pioglitazone); VFA=visceral fat area; WC=waist circumference.128 Diabetes Ther (2010)  1(2):121-130.
In this study, we evaluated patients’ insulin 
resistance after hyperglycemia was ameliorated. 
Defects in insulin action were induced only 
after 24 hours of hyperglycemia in patients 
with type 1 diabetes.23 Insulin treatment for 4 
weeks and good glycemic control improved 
insulin resistance in patients with uncontrolled 
type 2 diabetes.24 Those studies indicated that 
hyperglycemia worsens insulin resistance, 
and that this augmented resistance could be 
recovered after glycemic control was improved. 
Therefore, we propose that the evaluation of 
insulin resistance should be performed after the 
amelioration of glycemic control.
In this study, we also analyzed the association 
between the effectiveness of insulin sensitizers 
and HOMA-IR, which was regarded as the 
reference parameter in cases with insulin 
therapy. When all of the patients were divided 
into two groups according to the median value 
of HOMA-IR (HOMA-IR ≥1.75, HOMA-IR <1.75), 
the levels of HbA1c did not change in both 
groups with insulin sensitizers, indicating that 
HOMA-IR was not also useful for determining 
the effectiveness of insulin sensitizers. 
HOMA-IR represents an index of the hepatic 
insulin sensitivity in the basal state,25 which 
does not necessarily parallel peripheral insulin 
sensitivity,26 while KITT represents in-vivo insulin 
action in the whole body directly.13 Indeed, the 
association between insulin resistance obtained 
from the homeostasis model assessment and the 
ITT was significant but quite low,27 suggesting 
that these two parameters represent different 
aspects of the insulin resistance. 
There are some study limitations to consider. 
First, this is a retrospective study, and we could 
not discriminate the effect of any medication 
other than insulin sensitizers, especially insulin, 
on glycemic control after discharge. However, the 
ratio of patients using insulin in the KITT ≤1.56 
group with insulin sensitizers was not higher 
than those of other groups. Similarly, the ratio 
of patients using treatment other than insulin 
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Figure 2. Glycemic control after discharge. Glycemic control around the time of discharge and 6 months after discharge are 
shown. The levels of hemoglobin A1c (HbA1c) significantly increased in the rate constant for plasma glucose disappearance 
calculated from the insulin tolerance test (KITT) ≤1.56 without insulin sensitizers group, the KITT >1.56 with insulin sensitizers 
group and the KITT >1.56 without insulin sensitizers group. However, HbA1c did not increase in the KITT ≤1.56 with insulin 
sensitizers group. BG=biguanide (metformin or buformine); NS=not significant; TZD=thiazolidinediones (pioglitazone).Diabetes Ther (2010)  1(2):121-130. 129
sensitizers was the same as that in the KITT >1.56 
group with insulin sensitizers. Therefore, the 
good glycemic control obtained in the KITT ≤1.56 
group with insulin sensitizers might be derived 
from the higher insulin resistance estimated by 
ITT, and the efficacy of insulin sensitizers. Also, 
patients with insulin sensitizers were not selected 
at random. The numbers of patients with insulin 
sensitizers in the KITT ≤1.56 and the KITT >1.56 
groups are different and small. However, our 
data showed the significant difference of the 
effectiveness of insulin sensitizers among these 
subgroups. 
CONCLUSION
In summary, insulin sensitizers were more 
effective for glycemic control in type 2 diabetic 
patients with higher insulin resistance estimated 
by the ITT. The ITT could be useful for predicting 
the effectiveness of insulin sensitizers. Further 
prospective studies are needed to confirm the 
usefulness of the ITT.
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